All In Biotech

Drug Trial Radar · NCT02249429

Open-Label, Non Randomized Phase 2 Study With Safety Run-In

Open-Label, Non Randomized Phase 2 Study With Safety Run-In Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Lymphoma

Last checked: Nov 19, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

53

Actual

Start

May 2015

Primary completion

Sep 11, 2018

Study completion Sep 11, 2018

Sponsor

Lead sponsor
PIQUR Therapeutics AGIndustry
Sponsor type
Industry
Collaborators
University College London Hospitals; Churchill Hospital; Royal Marsden NHS Foundation Trust; University of Haifa; Weill Medical College of Cornell University; Institut Curie; University Clinical Center, Sarajevo; Clinical Center Kragujevac; Clinical Center Nis, Nis; Institute for Oncology and Radiology Serbia, Belgrade; University Clinical Centre of Republic of Srpska
First posted
Sep 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goal of this study is to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) as well as preliminary antitumor activity of bimiralisib (PQR309) administered orally, as once daily capsules continuously and on intermittent schedule in patients with relapsed or refractory lymphomas.

Conditions

  • Lymphoma, Malignant

Interventions

  • bimiralisibDrug

    60 mg or 80 mg bimiralisib per oral (p.o.) once daily or intermittent dosing (120mg,140mg and 160mg) until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of Change of Tumor Response Criteria in lymphoma patients During Treatment with PQR309 in patients with relapsed or refractory lymphoma according to Cheston Criteria (5)Time frame: 28 day prior to first treatment (baseline), during treatment every 8 weeks during 6 months and every 6 months afterwards up to 1 year)

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • Weill Cornell Medicine

    New York, New York

  • University Clinical Center Republic of Srpska

    Banja Luka, Bosnia and Herzegovina

  • University Clinical Center Sarajevo

    Sarajevo, Bosnia and Herzegovina

  • Insitute Curie

    Saint-Cloud, Paris, France

  • Univeristy Hospital Haifa

    Haifa, Israel

  • Institute for Oncology and radiology of Serbia

    Belgrade, Serbia

  • Clinical Center Kragujevac

    Kragujevac, Serbia

  • Clinical Center Nis

    Niš, Serbia

  • Guy's Hospital

    London, United Kingdom

  • Royal Marsden NHS Foundation Trust

    London, United Kingdom

  • University College Hospital London

    London, United Kingdom

  • Churchill Hospital

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.